Literature DB >> 19879047

Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids.

Alejandro Telleria-Diaz1, Martin Schmidt, Stefan Kreusch, Anne-Kathrin Neubert, Florian Schache, Enrique Vazquez, Horacio Vanegas, Hans-Georg Schaible, Andrea Ebersberger.   

Abstract

Both cyclooxygenase-1 and -2 are expressed in the spinal cord, and the spinal COX product prostaglandin E(2) (PGE(2)) contributes to the generation of central sensitization upon peripheral inflammation. Vice versa spinal COX inhibition is considered an important mechanism of antihyperalgesic pain treatment. Recently, however, COX-2 was shown to be also involved in the metabolism of endocannabinoids. Because endocannabinoids can have analgesic actions it is conceivable that inhibition of spinal COX produces analgesia not only by inhibition of PG synthesis but also by inhibition of endocannabinoid breakdown. In the present study, we recorded from spinal cord neurons with input from the inflamed knee joint and we measured the spinal release of PGE(2) and the endocannabinoid 2-arachidonoyl glycerol (2-AG) in vivo, using the same stimulation procedures. COX inhibitors were applied spinally. Selective COX-1, selective COX-2 and non-selective COX inhibitors attenuated the generation of spinal hyperexcitability when applied before and during development of inflammation but, when inflammation and spinal hyperexcitability were established, only selective COX-2 inhibitors reversed spinal hyperexcitability. During established inflammation all COX inhibitors reduced release of spinal PGE(2) almost equally but only the COX-2 inhibitor prevented breakdown of 2-AG. The reversal of spinal hyperexcitability by COX-2 inhibitors was prevented or partially reversed by AM-251, an antagonist at the cannabinoid-1 receptor. We conclude that inhibition of spinal COX-2 not only reduces PG production but also endocannabinoid breakdown and provide evidence that reversal of inflammation-evoked spinal hyperexcitability by COX-2 inhibitors is more related to endocannabinoidergic mechanisms than to inhibition of spinal PG synthesis. Copyright 2009 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879047     DOI: 10.1016/j.pain.2009.08.013

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  35 in total

Review 1.  [Pharmacological aspects of pain research in Germany].

Authors:  E Niederberger; R Kuner; G Geißlinger
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.

Authors:  Oscar Sasso; Rosalia Bertorelli; Tiziano Bandiera; Rita Scarpelli; Giampiero Colombano; Andrea Armirotti; Guillermo Moreno-Sanz; Angelo Reggiani; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2012-03-07       Impact factor: 7.658

Review 4.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

5.  COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation.

Authors:  A Straiker; J Wager-Miller; S S Hu; J L Blankman; B F Cravatt; K Mackie
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

6.  Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids.

Authors:  L E Staniaszek; L M Norris; D A Kendall; D A Barrett; V Chapman
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 8.  ABHD6: Its Place in Endocannabinoid Signaling and Beyond.

Authors:  Jessica K Cao; Joshua Kaplan; Nephi Stella
Journal:  Trends Pharmacol Sci       Date:  2019-03-07       Impact factor: 14.819

9.  Artesunate Ameliorates Functional Limitations in Freund's Complete Adjuvant-Induced Monoarthritis in Rat by Maintaining Oxidative Homeostasis and Inhibiting COX-2 Expression.

Authors:  B Guruprasad; Priyanka Chaudhary; Tenzin Choedon; Vijay L Kumar
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

10.  Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain.

Authors:  Axel Becker; Gerd Geisslinger; Radovan Murín; Gisela Grecksch; Volker Höllt; Andreas Zimmer; Helmut Schröder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.